Network metanalysis & review looked at Biologics & remission in Crohns disease (25 RCTs; 8720 pts). -Compared to PBO Rankings were #1) infliximab 5 mg/kg (RR=0.67), #2) risankizumab 600 mg, #3) upadacitinib 45 mg. RIZ was 1st in biologic-naïve pts https://t.co/JFTEpqSJ6c https://t.co/65vbZkLmpC